Animal Health: Veterinary Vaccine Development

Streamline vaccine development with operational efficiency and flexible study design Veterinary vaccine development is crucial for animal health, public safety and food security by helping to prevent zoonotic diseases, reduce antibiotic use and protect livestock productivity. However, challenges like disease variations, regulatory hurdles, high costs, cold chain logistics, species-specific efficacy and public reluctance hinder widespread adoption.

Extraction Vehicle Selection for the Material Mediated Pyrogen Test

Following submission of a package to a regulatory body, it is typical to receive feedback regarding some portion of the submission, including biocompatibility. Recently, Labcorp provided guidance to a client who needed help responding to a submission finding that we had previously navigated. We share both the finding and response below. Sharing common or important findings, and the responses to them, can help the community and regulators better understand the evaluation methods and ensure that future submissions are as successful as possible.

Site neutrality and future-proofing the laboratory

Bryan Vaughn, senior vice president of health systems at Labcorp, shares his perspective on site neutrality and how to future-proof the lab. For health system leaders, early 2025 has been a whirlwind of potential policy changes – from Medicaid funding to NIH grants – that could impact providers in a material, long-term manner.  Underlying and apart from policy uncertainty, 2025 could well be an inflection point for healthcare costs.  

Labcorp Announces 2025 First Quarter Results

Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:

Society of Environmental Toxicology and Chemistry (SETAC) Europe 35th Annual Meeting

Let’s connect at the Society of Environmental Toxicology and Chemistry (SETAC) Europe 35th Annual Meeting at the Austria Center Vienna, Austria, from May 11-15.  

Prenatal Testing: The Importance of Early Preeclampsia and Genetic Screening in Pregnancy

Early preeclampsia and genetic screening in pregnancy can identify conditions that may increase risk for fetal and maternal complications. Insights from these screenings can help your patients better prepare for the future.In our webinar, you'll learn how early preeclampsia screening and the latest developments in cell-free DNA (cfDNA) noninvasive prenatal testing (NIPT) can help you improve maternal and perinatal outcomes.

On-Demand Webinar: Systemic Mastocytosis - Insights Into A Rare Blood Disorder

Presented by guest speaker Dr. Alejandro Gru, MD, Professor of Dermatology and Director of Dermapathology at Columbia University’s Irving Medical Center, this webinar provides information about systemic mastocytosis, a rare blood disorder where abnormal mast cells (white blood cells) build up in different parts of the human body, resulting in a variety of symptoms. It is estimated that over 32,000 United States citizens could be living with this disease, and this webinar profiles what causes systemic mastocytosis, how this condition affects patients, how systemic mastocytosis can be detected and how are patients being treated for this disease.

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Labcorp ® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio ® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ --  Labcorp  (NYSE:

Labcorp Acquires Select Assets of North Mississippi Health Services’ Ambulatory Outreach Laboratory Business

Precision healthcare: The role of genetic testing and lab data in improving patient outcomes

Today, precision medicine provides a biological approach to treatment that considers a patient's genomic information, as well as environmental, lifestyle and social factors. Advancements in genomic testing are fundamentally changing care for cancer and other conditions. These exciting developments, under the umbrella of precision healthcare, are leading to more personalized healthcare delivery that offers competitive advantages to hospitals and health systems embracing this approach. These were key themes of an executive session sponsored by Labcorp at Becker's 12th Annual CEO + CFO Roundtable. In this discussion, three Labcorp leaders- Mahul B. Amin, MD, vice president and divisional medical director; Ken Cerney, vice president of commercial operations; and Ed Esplin, MD, PhD, clinical geneticist and medical director- focused on the role of lab data and genetic testing in the journey to precision medicine and personalized healthcare delivery.In August 2024, Invitae became part of Labcorp to further the future of genetic testing. With Invitae, Labcorp extends its leadership in specialty testing with the most comprehensive offerings in areas such as oncology and select rare diseases and advances its mission to improve health and improve lives.